Liquid Biopsy in Pediatric Acute Lymphoblastic Leukemia (ALL)
-
By
-
Chen, Yingcong
-
Wang, Jie
-
Ye, Cuiying
-
Xu, Xudong
-
Yue, Meina
-
Zhao, Xinfeng
-
June 22, 2026
-
Clinical Scorecard: Utilization of Liquid Biopsy Techniques in Childhood Acute Lymphoblastic Leukemia (ALL)
At a Glance
| Category | Detail |
|---|
| Condition | Acute Lymphoblastic Leukemia (ALL) |
| Key Mechanisms | Liquid biopsy technologies including circulating tumor DNA (ctDNA), circulating microRNAs (miRNAs), and extracellular vesicles (EVs) |
| Target Population | Pediatric patients with Acute Lymphoblastic Leukemia |
| Care Setting | Hematologic malignancies |
Key Highlights
- Liquid biopsy offers a minimally invasive method for real-time disease monitoring.
- ctDNA, miRNAs, and EVs are key components in the assessment of pediatric ALL.
- Challenges include limited blood volume and pre-analytical variability in children.
- Bone marrow evaluation remains the gold standard for diagnosis and MRD monitoring.
- Innovations in EV isolation and machine learning are enhancing biomarker integration.
Guideline-Based Recommendations
Diagnosis
- Bone marrow evaluation is essential for diagnosis.
Management
- Liquid biopsy technologies can complement traditional methods for individualized patient management.
Monitoring & Follow-up
- Liquid biopsy can be used for measurable residual disease (MRD) assessment.
Risks
- Pre-analytical variability may affect the reliability of liquid biopsy results.
Patient & Prescribing Data
Pediatric patients with ALL
Liquid biopsy approaches are in early translational stages and require further validation.
Clinical Best Practices
- Utilize liquid biopsy as a complementary tool alongside traditional diagnostic methods.
- Focus on developing sensitive assays tailored to pediatric patients.
Related Resources & Content
